Search

Your search keyword '"Meijer, Richard P"' showing total 468 results
Start Over Author "Meijer, Richard P"
468 results on '"Meijer, Richard P"'

1. Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer

Author

Vlaming, Michiel, Ausems, Margreet G. E. M., Kiemeney, Lambertus A. L. M., Schijven, Gina, van Melick, Harm H. E., Noordzij, M. Arjen, Somford, Diederik M., van der Poel, Henk G., Wijburg, Carl J., Wijsman, Bart P., Hoekstra, Robert J., van Moorselaar, Reindert J. A., van Bezooijen, Bart P. J., Meijer, Richard P., Busstra, Martijn B., van den Berg, H. Pieter, Robbrecht, Debbie G. J., Doornweerd, Benjamin H. J., Bleiker, Eveline M. A., and van Oort, Inge M.

Published
2024
Full Text
View/download PDF

4. Short-term Changes in Health-related Quality of Life of Patients Undergoing Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: Results from a Prospective Phase 2 Clinical Trial

Author

van Doeveren, Thomas, Remmers, Sebastiaan, Atema, Vera, van den Bergh, Roderick C.N., Boevé, Egbert R., Cornel, Erik B., van der Heijden, Antoine G., Hendricksen, Kees, Cauberg, Evelyne C.C., Jacobs, Rens A.L., Kroon, Bin K., Leliveld, Annemarie M., Meijer, Richard P., Merks, Bob, Oddens, Jorg R., Roelofs, Luc, Somford, Diederik M., de Vries, Peter, Wijsman, Bart, Windt, Willemijn A.K.M., Zwaan, Peter J., van Leeuwen, Pim J., Boormans, Joost L., and Aben, Katja K.H.

Published
2024
Full Text
View/download PDF

5. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

Author

Mertens, Laura S., Bruins, Harman Maxim, Contieri, Roberto, Babjuk, Marek, Rai, Bhavan P., Puig, Albert Carrión, Escrig, Jose Luis Dominguez, Gontero, Paolo, van der Heijden, Antoine G., Liedberg, Fredrik, Martini, Alberto, Masson-Lecomte, Alexandra, Meijer, Richard P., Mostafid, Hugh, Neuzillet, Yann, Pradere, Benjamin, Redlef, John, van Rhijn, Bas W.G., Rouanne, Matthieu, Rouprêt, Morgan, Sæbjørnsen, Sæbjørn, Seisen, Thomas, Shariat, Shahrokh F., Soria, Francesco, Soukup, Viktor, Thalmann, George, Xylinas, Evanguelos, Mariappan, Paramananthan, and Alfred Witjes, J.

Published
2024
Full Text
View/download PDF

6. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

Author

Alfred Witjes, J., Max Bruins, Harman, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A., Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S., Meijer, Richard P., Milowsky, Matthew I., Neuzillet, Yann, Panebianco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N., Sæbjørnsen, Sæbjørn, Veskimäe, Erik, and van der Heijden, Antoine G.

Published
2024
Full Text
View/download PDF

7. Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Author

van Dorp, Jeroen, Pipinikas, Christodoulos, Suelmann, Britt B. M., Mehra, Niven, van Dijk, Nick, Marsico, Giovanni, van Montfoort, Maurits L., Hackinger, Sophie, Braaf, Linde M., Amarante, Tauanne, van Steenis, Charlaine, McLay, Kirsten, Daletzakis, Antonios, van den Broek, Daan, van de Kamp, Maaike W., Hendricksen, Kees, de Feijter, Jeantine M., Boellaard, Thierry N., Meijer, Richard P., van der Heijden, Antoine G., Rosenfeld, Nitzan, van Rhijn, Bas W. G., Jones, Greg, and van der Heijden, Michiel S.

Published
2024
Full Text
View/download PDF

8. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Author

van Dorp, Jeroen, Pipinikas, Christodoulos, Suelmann, Britt B. M., Mehra, Niven, van Dijk, Nick, Marsico, Giovanni, van Montfoort, Maurits L., Hackinger, Sophie, Braaf, Linde M., Amarante, Tauanne, van Steenis, Charlaine, McLay, Kirsten, Daletzakis, Antonios, van den Broek, Daan, van de Kamp, Maaike W., Hendricksen, Kees, de Feijter, Jeantine M., Boellaard, Thierry N., Meijer, Richard P., van der Heijden, Antoine G., Rosenfeld, Nitzan, van Rhijn, Bas W. G., Jones, Greg, and van der Heijden, Michiel S.

Published
2023
Full Text
View/download PDF

15. Robot-assisted Versus Open Radical Cystectomy in Bladder Cancer: An Economic Evaluation Alongside a Multicentre Comparative Effectiveness Study

Author

Helder, Sip, Venderbosch, Guus, Calsbeek, Hilly, Wijburg, Carl J., Witjes, J. Alfred, Onna, Ilze E.W.van, Barten, Evert J., Koldewijn, Evert L., Boormans, Joost L., Wijsman, Bart P., Nooter, Ronald I., Zwaan, Peter J., Slaa, Ed te, Meer, Saskia van der, Klaver, Sjoerd O., Fossion, Laurent M.C.L., Bos, Siebe D., Melick, Harm H.E.van, Leliveld, Anna M., Meijer, Richard P., Vis, André N., Molijn, Gerard J., Berendsen, Chris L., Oddens, Jorg R., Michels, Charlotte T.J., Hannink, Gerjon, Rovers, Maroeska M., and Grutters, Janneke P.C.

Published
2022
Full Text
View/download PDF

17. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study

Author

Wijburg, Carl J., Witjes, J. Alfred, van Onna, Ilze E.W., Barten, Evert J., Koldewijn, Evert L., Boormans, Joost L., Wijsman, Bart P., Nooter, Ronald I., Zwaan, Peter J., Slaa, Ed te, Meer, Saskia van der, Klaver, Sjoerd O., Fossion, Laurent M.C.L., Bos, Siebe D., Melick, Harm H.E.van, Leliveld, Anna M., Meijer, Richard P., Vis, André N., Molijn, Gerard J., Berendsen, Chris L., Oddens, Jorg R., Michels, Charlotte T.J., Hannink, Gerjon, Grutters, Janneke P.C., Rovers, Maroeska M., and Alfred Witjes, J.

Published
2021
Full Text
View/download PDF

19. Short-term Changes in Health-related Quality of Life of Patients Undergoing Radical Surgery for Upper Urinary Tract Urothelial Carcinoma:Results from a Prospective Phase 2 Clinical Trial

Author

van Doeveren, Thomas, Remmers, Sebastiaan, Atema, Vera, van den Bergh, Roderick C N, Boevé, Egbert R, Cornel, Erik B, van der Heijden, Antoine G, Hendricksen, Kees, Cauberg, Evelyne C C, Jacobs, Rens A L, Kroon, Bin K, Leliveld, Annemarie M, Meijer, Richard P, Merks, Bob, Oddens, Jorg R, Roelofs, Luc, Somford, Diederik M, de Vries, Peter, Wijsman, Bart, Windt, Willemijn A K M, Zwaan, Peter J, van Leeuwen, Pim J, Boormans, Joost L, Aben, Katja K H, van Doeveren, Thomas, Remmers, Sebastiaan, Atema, Vera, van den Bergh, Roderick C N, Boevé, Egbert R, Cornel, Erik B, van der Heijden, Antoine G, Hendricksen, Kees, Cauberg, Evelyne C C, Jacobs, Rens A L, Kroon, Bin K, Leliveld, Annemarie M, Meijer, Richard P, Merks, Bob, Oddens, Jorg R, Roelofs, Luc, Somford, Diederik M, de Vries, Peter, Wijsman, Bart, Windt, Willemijn A K M, Zwaan, Peter J, van Leeuwen, Pim J, Boormans, Joost L, and Aben, Katja K H

Abstract

BACKGROUND AND OBJECTIVE: The possible negative impact of radical surgery on patients' health-related quality of life (HRQoL) plays an important role in preoperative counseling. Here, we analyzed the HRQoL of patients treated for upper urinary tract urothelial carcinoma (UTUC) in the context of a single-arm phase 2 multicenter study, in which the safety and efficacy of a single preoperative intravesical instillation with mitomycin C were investigated. Our objective was to investigate early changes in HRQoL in patients undergoing radical surgery for UTUC and identify factors associated with these outcomes.METHODS: Patients with pTanyN0-1M0 UTUC were prospectively included. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire at baseline, and at 1 and 3 mo after surgery. A linear mixed model was used to evaluate the changes in HRQoL over time and identify the variables associated with these outcomes. The clinical effect size was used to assess the clinical impact and level of perceptibility of HRQoL changes for clinicians and/or patients based on given thresholds.KEY FINDINGS AND LIMITATIONS: Between 2017 and 2020, 186 patients were included. At baseline, 1 mo after surgery, and 3 mo after surgery, response rates were 91%, 84%, and 78%, respectively. One month after surgery, a statistically significant and clinically relevant deterioration was observed in physical, role, and social functioning, and for the included symptom scales: constipation, fatigue, and pain. An improvement in emotional functioning was observed. At 3 mo, HRQoL returned to baseline levels, except emotional functioning, which improved at 1 mo and persisted to be better than that before surgery. Age >70 yr was associated with worse physical functioning, but better social and emotional functioning. Male patients reported better emotional functioning than fe

Published
2024

20. Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

Author

Richters, Anke, Robbrecht, Debbie G.J., Meijer, Richard P., van der Heijden, Antoine G., Kiemeney, Lambertus A.L.M., van den Bosch, Joan, Suelmann, Britt B.M., Özdemir, Berna C., Mehra, Niven, Aben, Katja K.H., Richters, Anke, Robbrecht, Debbie G.J., Meijer, Richard P., van der Heijden, Antoine G., Kiemeney, Lambertus A.L.M., van den Bosch, Joan, Suelmann, Britt B.M., Özdemir, Berna C., Mehra, Niven, and Aben, Katja K.H.

Abstract

Since 2017, two immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of metastatic urothelial carcinoma in Europe: pembrolizumab as second-line therapy and avelumab as maintenance therapy. Our aim was to describe the use of ICIs as first and later lines of treatment in patients with metastatic bladder cancer (mBC) in the Netherlands. We identified all patients diagnosed with primary mBC between 2018 and 2021 in the Netherlands from the Netherlands Cancer Registry (NCR). NCR data were supplemented with data from the Dutch nationwide Prospective Bladder Cancer Infrastructure (ProBCI) collected from medical files, with follow-up until death or end of data collection on January 1, 2023. A total of 1525 patients were diagnosed with primary mBC between 2018 and 2021 in the Netherlands. Of these, 34.7% received at least one line of systemic treatment with chemotherapy or ICI. After first-line platinum-based chemotherapy, 34.1% received second-line ICI and 3.9% received maintenance ICI. Among patients who completed or discontinued first-line cisplatin- or carboplatin-based chemotherapy after approval of maintenance ICI in the Netherlands, 40.7% and 19.7% received second-line ICI, and 9.3% and 14.1% received maintenance ICI, respectively. ICI use for mBC treatment has not increased considerably since their introduction in 2017. Future research should assess whether the introduction of maintenance avelumab (available since April 2021 in the Netherlands) has led to increases in the proportion of patients with mBC patients receiving systemic treatment and the proportion receiving ICI. Patient summary: We assessed the rate of immunotherapy use for patients with metastatic bladder cancer in the Netherlands. Since its introduction, immunotherapy has been used in a minority of patients, mostly as second-line treatment after platinum-based chemotherapy.

Published
2024

21. Corrigendum to 'European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31, (S0302283823030737), (10.1016/j.eururo.2023.08.016)]

Author

MS Urologische Oncologie, Cancer, Alfred Witjes, J, Bruins, Harman Max, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A, Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S, Meijer, Richard P, Milowsky, Matthew I, Neuzillet, Yann, Panebiaco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N, Sæbjørnsen, Sæbjørn, Veskimäe, Erik, Mariappan, Paramananthan, van der Heijden, Antoine G, MS Urologische Oncologie, Cancer, Alfred Witjes, J, Bruins, Harman Max, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A, Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S, Meijer, Richard P, Milowsky, Matthew I, Neuzillet, Yann, Panebiaco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N, Sæbjørnsen, Sæbjørn, Veskimäe, Erik, Mariappan, Paramananthan, and van der Heijden, Antoine G

Published
2024

22. Perspectives and Concerns on Late Effects Regarding Sexuality among Adolescents and Young Adults Treated for Testicular Germ Cell Tumor: The PRICELESS-Study-A Qualitative Study

Author

Verplegingswetenschap, MS Medische Oncologie, Cancer, MS Urologische Oncologie, Kuiper, Stefan T, Zweers, Daniëlle, Suelmann, Britt B M, Meijer, Richard P, Vervoort, Sigrid C J M, Verplegingswetenschap, MS Medische Oncologie, Cancer, MS Urologische Oncologie, Kuiper, Stefan T, Zweers, Daniëlle, Suelmann, Britt B M, Meijer, Richard P, and Vervoort, Sigrid C J M

Published
2024

23. Short-term Changes in Health-related Quality of Life of Patients Undergoing Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: Results from a Prospective Phase 2 Clinical Trial

Author

Zorgeenheid Urologie Medisch, MS Urologische Oncologie, Cancer, van Doeveren, Thomas, Remmers, Sebastiaan, Atema, Vera, van den Bergh, Roderick C.N., Boevé, Egbert R., Cornel, Erik B., van der Heijden, Antoine G., Hendricksen, Kees, Cauberg, Evelyne C.C., Jacobs, Rens A.L., Kroon, Bin K., Leliveld, Annemarie M., Meijer, Richard P., Merks, Bob, Oddens, Jorg R., Roelofs, Luc, Somford, Diederik M., de Vries, Peter, Wijsman, Bart, Windt, Willemijn A.K.M., Zwaan, Peter J., van Leeuwen, Pim J., Boormans, Joost L., Aben, Katja K.H., Zorgeenheid Urologie Medisch, MS Urologische Oncologie, Cancer, van Doeveren, Thomas, Remmers, Sebastiaan, Atema, Vera, van den Bergh, Roderick C.N., Boevé, Egbert R., Cornel, Erik B., van der Heijden, Antoine G., Hendricksen, Kees, Cauberg, Evelyne C.C., Jacobs, Rens A.L., Kroon, Bin K., Leliveld, Annemarie M., Meijer, Richard P., Merks, Bob, Oddens, Jorg R., Roelofs, Luc, Somford, Diederik M., de Vries, Peter, Wijsman, Bart, Windt, Willemijn A.K.M., Zwaan, Peter J., van Leeuwen, Pim J., Boormans, Joost L., and Aben, Katja K.H.

Published
2024

24. Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

Author

Cancer, MS Medische Oncologie, MS Urologische Oncologie, van Dorp, Jeroen, Pipinikas, Christodoulos, Suelmann, Britt B M, Mehra, Niven, van Dijk, Nick, Marsico, Giovanni, van Montfoort, Maurits L, Hackinger, Sophie, Braaf, Linde M, Amarante, Tauanne, van Steenis, Charlaine, McLay, Kirsten, Daletzakis, Antonios, van den Broek, Daan, van de Kamp, Maaike W, Hendricksen, Kees, de Feijter, Jeantine M, Boellaard, Thierry N, Meijer, Richard P, van der Heijden, Antoine G, Rosenfeld, Nitzan, van Rhijn, Bas W G, Jones, Greg, van der Heijden, Michiel S, Cancer, MS Medische Oncologie, MS Urologische Oncologie, van Dorp, Jeroen, Pipinikas, Christodoulos, Suelmann, Britt B M, Mehra, Niven, van Dijk, Nick, Marsico, Giovanni, van Montfoort, Maurits L, Hackinger, Sophie, Braaf, Linde M, Amarante, Tauanne, van Steenis, Charlaine, McLay, Kirsten, Daletzakis, Antonios, van den Broek, Daan, van de Kamp, Maaike W, Hendricksen, Kees, de Feijter, Jeantine M, Boellaard, Thierry N, Meijer, Richard P, van der Heijden, Antoine G, Rosenfeld, Nitzan, van Rhijn, Bas W G, Jones, Greg, and van der Heijden, Michiel S

Published
2024

25. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation

Author

Cancer, MS Urologische Oncologie, Pathologie Pathologen staf, Hubrecht Institute with UMC, Viergever, Bastiaan J, Raats, Daniëlle A E, Geurts, Veerle, Mullenders, Jasper, Jonges, Trudy N, van der Heijden, Michiel S, van Es, Johan H, Kranenburg, Onno, Meijer, Richard P, Cancer, MS Urologische Oncologie, Pathologie Pathologen staf, Hubrecht Institute with UMC, Viergever, Bastiaan J, Raats, Daniëlle A E, Geurts, Veerle, Mullenders, Jasper, Jonges, Trudy N, van der Heijden, Michiel S, van Es, Johan H, Kranenburg, Onno, and Meijer, Richard P

Published
2024

26. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

Author

MS Urologische Oncologie, Cancer, Alfred Witjes, J, Max Bruins, Harman, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A, Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S, Meijer, Richard P, Milowsky, Matthew I, Neuzillet, Yann, Panebianco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N, Sæbjørnsen, Sæbjørn, Veskimäe, Erik, van der Heijden, Antoine G, MS Urologische Oncologie, Cancer, Alfred Witjes, J, Max Bruins, Harman, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A, Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S, Meijer, Richard P, Milowsky, Matthew I, Neuzillet, Yann, Panebianco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N, Sæbjørnsen, Sæbjørn, Veskimäe, Erik, and van der Heijden, Antoine G

Published
2024

27. Use of the ISUP e-learning module improves interrater reliability in prostate cancer grading

Author

MS Urologische Oncologie, Cancer, Pathologie, Flach, Rachel N, Egevad, Lars, Eklund, Martin, van der Kwast, Theodorus H, Delahunt, Brett, Samaratunga, Hemamali, Suelmann, Britt B M, Willemse, Peter-Paul M, Meijer, Richard P, van Diest, Paul J, MS Urologische Oncologie, Cancer, Pathologie, Flach, Rachel N, Egevad, Lars, Eklund, Martin, van der Kwast, Theodorus H, Delahunt, Brett, Samaratunga, Hemamali, Suelmann, Britt B M, Willemse, Peter-Paul M, Meijer, Richard P, and van Diest, Paul J

Published
2024

32. Corrigendum to “European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31]

Author

Alfred Witjes, J., primary, Bruins, Harman Max, additional, Carrión, Albert, additional, Cathomas, Richard, additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Fietkau, Rainer, additional, Gakis, Georgios, additional, Lorch, Anja, additional, Martini, Alberto, additional, Mertens, Laura S., additional, Meijer, Richard P., additional, Milowsky, Matthew I., additional, Neuzillet, Yann, additional, Panebiaco, Valeria, additional, Redlef, John, additional, Rink, Michael, additional, Rouanne, Mathieu, additional, Thalmann, George N., additional, Sæbjørnsen, Sæbjørn, additional, Veskimäe, Erik, additional, Mariappan, Paramananthan, additional, and van der Heijden, Antoine G., additional

Published
2024
Full Text
View/download PDF

35. Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

Author

Richters, Anke, primary, Robbrecht, Debbie G.J., additional, Meijer, Richard P., additional, van der Heijden, Antoine G., additional, Kiemeney, Lambertus A.L.M., additional, van den Bosch, Joan, additional, Suelmann, Britt B.M., additional, Özdemir, Berna C., additional, Mehra, Niven, additional, and Aben, Katja K.H., additional

Published
2024
Full Text
View/download PDF

36. Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study

Author

Brück, Katharina, primary, Meijer, Richard P., additional, Boormans, Joost L., additional, Kiemeney, Lambertus A., additional, Witjes, J. Alfred, additional, van Hoogstraten, Lisa M.C., additional, van der Heijden, Michiel S., additional, Donders, A. Rogier, additional, Franckena, Martine, additional, Uyl de Groot, Carin A., additional, Leliveld, Annemarie M., additional, Aben, Katja K.H., additional, and Hulshof, Maarten C.C.M., additional

Published
2024
Full Text
View/download PDF

40. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

Author

Alfred Witjes, J., primary, Max Bruins, Harman, additional, Carrión, Albert, additional, Cathomas, Richard, additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Fietkau, Rainer, additional, Gakis, Georgios, additional, Lorch, Anja, additional, Martini, Alberto, additional, Mertens, Laura S., additional, Meijer, Richard P., additional, Milowsky, Matthew I., additional, Neuzillet, Yann, additional, Panebianco, Valeria, additional, Redlef, John, additional, Rink, Michael, additional, Rouanne, Mathieu, additional, Thalmann, George N., additional, Sæbjørnsen, Sæbjørn, additional, Veskimäe, Erik, additional, and van der Heijden, Antoine G., additional

Published
2023
Full Text
View/download PDF

41. Recurrence pattern in localized RCC: results from a European multicenter database (RECUR)

Author

Fallara, Giuseppe, Larcher, Alessandro, Dabestani, Saeed, Fossati, Nicola, Järvinen, Petrus, Nisen, Harry, Gudmundsson, Eirikur, Lam, Thomas B., Marconi, Lorenzo, Fernandéz-Pello, Sergio, Meijer, Richard P., Volpe, Alessandro, Beisland, Christian, Klatte, Tobias, Stewart, Grant D., Bensalah, Karim, Ljungberg, Börje, Bertini, Roberto, Montorsi, Francesco, Bex, Axel, and Capitanio, Umberto

Published
2022
Full Text
View/download PDF

48. Feasibility of clinical studies of chemical exchange saturation transfer magnetic resonance imaging of prostate cancer at 7 T

Author

Reesink, Daan J., primary, Arteaga de Castro, Catalina S., additional, Van der Velden, Tijl, additional, Van Vooren, Jeanette, additional, Oost, Petri, additional, Jonges, Trudy G.N., additional, Lam, Marnix G. E. H., additional, de Keizer, Bart, additional, Willemse, Peter‐Paul M., additional, Meijer, Richard P., additional, and Klomp, Dennis W. J., additional

Published
2023
Full Text
View/download PDF

49. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study

Author

Haar-Holleman, Amy de, Hoogstraten, L.M.C. van, Hulshof, Maarten C.C.M., Tascilar, M., Bruck, Katharin, Witjes, J.A., Meijer, Richard P., Kiemeney, B., Aben, K.K.H., Haar-Holleman, Amy de, Hoogstraten, L.M.C. van, Hulshof, Maarten C.C.M., Tascilar, M., Bruck, Katharin, Witjes, J.A., Meijer, Richard P., Kiemeney, B., and Aben, K.K.H.

Abstract

Item does not contain fulltext

Published
2023

50. EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy:protocol of the ENHANCE multicentre randomised controlled trial

Author

Akdemir, Emine, Sweegers, Maike G., Vrieling, Alina, Rundqvist, Helene, Meijer, Richard P., Leliveld-Kors, Annemarie M., Van Der Heijden, Antoine G., Rutten, Vera C., Koldewijn, Evert L., Bos, Siebe D., Wijburg, Carl J., Marcelissen, Tom A.T., Bongers, Bart C., Retèl, Valesca P., Van Harten, Wim H., May, Anne M., Groen, Wim G., Stuiver, Martijn M., Akdemir, Emine, Sweegers, Maike G., Vrieling, Alina, Rundqvist, Helene, Meijer, Richard P., Leliveld-Kors, Annemarie M., Van Der Heijden, Antoine G., Rutten, Vera C., Koldewijn, Evert L., Bos, Siebe D., Wijburg, Carl J., Marcelissen, Tom A.T., Bongers, Bart C., Retèl, Valesca P., Van Harten, Wim H., May, Anne M., Groen, Wim G., and Stuiver, Martijn M.

Abstract

Introduction Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50-65% of patients undergoing RC experience perioperative complications. The risk, severity and impact of these complications is associated with a patient's preoperative cardiorespiratory fitness, nutritional and smoking status and presence of anxiety and depression. There is emerging evidence supporting multimodal prehabilitation as a strategy to reduce the risk of complications and improve functional recovery after major cancer surgery. However, for bladder cancer the evidence is still limited. The aim of this study is to investigate the superiority of a multimodal prehabilitation programme versus standard-of-care in terms of reducing perioperative complications in patients with bladder cancer undergoing RC. Methods and analysis This multicentre, open label, prospective, randomised controlled trial, will include 154 patients with bladder cancer undergoing RC. Patients are recruited from eight hospitals in The Netherlands and will be randomly (1:1) allocated to the intervention group receiving a structured multimodal prehabilitation programme of approximately 3-6 weeks, or to the control group receiving standard-of-care. The primary outcome is the proportion of patients who develop one or more grade ≥2 complications (according to the Clavien-Dindo classification) within 90 days of surgery. Secondary outcomes include cardiorespiratory fitness, length of hospital stay, health-related quality of life, tumour tissue biomarkers of hypoxia, immune cell infiltration and cost-effectiveness. Data collection will take place at baseline, before surgery and 4 and 12 weeks after surgery. Ethics and dissemination Ethical approval for this study was granted by the Medical Ethics Committee NedMec (Amsterdam, The Netherlands) under reference number 22

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results